Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy.

Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1177-82. doi: 10.1016/j.bmcl.2008.12.085. Epub 2008 Dec 25.

PMID:
19138846
2.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups.

Sparks SM, Banker P, Bickett DM, Carter HL, Clancy DC, Dickerson SH, Dwornik KA, Garrido DM, Golden PL, Nolte RT, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Wang L, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):976-80. doi: 10.1016/j.bmcl.2008.11.085. Epub 2008 Nov 27.

PMID:
19095442
3.

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues.

Sparks SM, Banker P, Bickett DM, Clancy DC, Dickerson SH, Garrido DM, Golden PL, Peat AJ, Sheckler LR, Tavares FX, Thomson SA, Weiel JE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):981-5. doi: 10.1016/j.bmcl.2008.11.084. Epub 2008 Nov 27.

PMID:
19095443
4.

Advances in glycogen phosphorylase inhibitor design.

Oikonomakos NG, Somsák L.

Curr Opin Investig Drugs. 2008 Apr;9(4):379-95. Review.

PMID:
18393105
5.

Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.

Kristiansen M, Andersen B, Iversen LF, Westergaard N.

J Med Chem. 2004 Jul 1;47(14):3537-45.

PMID:
15214781
6.

Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystallographic studies.

Wen X, Sun H, Liu J, Cheng K, Zhang P, Zhang L, Hao J, Zhang L, Ni P, Zographos SE, Leonidas DD, Alexacou KM, Gimisis T, Hayes JM, Oikonomakos NG.

J Med Chem. 2008 Jun 26;51(12):3540-54. doi: 10.1021/jm8000949. Epub 2008 Jun 3.

PMID:
18517260
7.

Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.

Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.

Curr Pharm Des. 2003;9(15):1177-89. Review.

PMID:
12769745
8.

Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors.

Ogawa AK, Willoughby CA, Bergeron R, Ellsworth KP, Geissler WM, Myers RW, Yao J, Harris G, Chapman KT.

Bioorg Med Chem Lett. 2003 Oct 20;13(20):3405-8.

PMID:
14505637
9.

Glycogen phosphorylase as a target for type 2 diabetes: synthetic, biochemical, structural and computational evaluation of novel N-acyl-N´-(β-D-glucopyranosyl) urea inhibitors.

Kantsadi AL, Parmenopoulou V, Bakalov DN, Snelgrove L, Stravodimos GA, Chatzileontiadou DS, Manta S, Panagiotopoulou A, Hayes JM, Komiotis D, Leonidas DD.

Curr Top Med Chem. 2015;15(23):2373-89.

PMID:
26088352
10.

Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.

Anderka O, Loenze P, Klabunde T, Dreyer MK, Defossa E, Wendt KU, Schmoll D.

Biochemistry. 2008 Apr 22;47(16):4683-91. doi: 10.1021/bi702397d. Epub 2008 Mar 29.

PMID:
18373353
11.

Human liver glycogen phosphorylase inhibitors bind at a new allosteric site.

Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR, Mathiowetz AM, McPherson RK, Olson TV, Treadway JL, Hoover DJ.

Chem Biol. 2000 Sep;7(9):677-82.

12.

Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.

Oikonomakos NG.

Curr Protein Pept Sci. 2002 Dec;3(6):561-86. Review.

PMID:
12470212
13.

Structural investigations of anthranilimide derivatives by CoMFA and CoMSIA 3D-QSAR studies reveal novel insight into their structures toward glycogen phosphorylase inhibition.

Saqib U, Kumar B, Siddiqi MI.

SAR QSAR Environ Res. 2011 Jul-Sep;22(5-6):411-49. doi: 10.1080/1062936X.2011.569898. Epub 2011 May 27.

PMID:
21607894
14.
15.

Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.

Whittamore PR, Addie MS, Bennett SN, Birch AM, Butters M, Godfrey L, Kenny PW, Morley AD, Murray PM, Oikonomakos NG, Otterbein LR, Pannifer AD, Parker JS, Readman K, Siedlecki PS, Schofield P, Stocker A, Taylor MJ, Townsend LA, Whalley DP, Whitehouse J.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5567-71. Epub 2006 Aug 30.

PMID:
16945526
16.

New inhibitors of glycogen phosphorylase as potential antidiabetic agents.

Somsák L, Czifrák K, Tóth M, Bokor E, Chrysina ED, Alexacou KM, Hayes JM, Tiraidis C, Lazoura E, Leonidas DD, Zographos SE, Oikonomakos NG.

Curr Med Chem. 2008;15(28):2933-83. Review.

PMID:
19075645
17.

Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes.

Kitas E, Mohr P, Kuhn B, Hebeisen P, Wessel HP, Haap W, Ruf A, Benz J, Joseph C, Huber W, Sanchez RA, Paehler A, Benardeau A, Gubler M, Schott B, Tozzo E.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):594-9. doi: 10.1016/j.bmcl.2009.11.093. Epub 2009 Nov 22.

PMID:
19969452
18.

1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.

Tsirkone VG, Tsoukala E, Lamprakis C, Manta S, Hayes JM, Skamnaki VT, Drakou C, Zographos SE, Komiotis D, Leonidas DD.

Bioorg Med Chem. 2010 May 15;18(10):3413-25. doi: 10.1016/j.bmc.2010.04.004. Epub 2010 Apr 7.

PMID:
20430629
19.

The prototype of glycogen phosphorylase.

Chrysina ED.

Mini Rev Med Chem. 2010 Oct;10(12):1093-101. Review.

PMID:
20716055
20.

Glycogen phosphorylase inhibitors.

Henke BR, Sparks SM.

Mini Rev Med Chem. 2006 Aug;6(8):845-57. Review.

PMID:
16918491

Supplemental Content

Support Center